Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Minerva Neurosciences Inc (NERV)

46 + Investors. Track Smart Money conviction in NERV. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↑ +13
Streak
3Q ▲
Buyers last Q
68%

Smart Money Signals — NERV

Based on 46 hedge funds · latest filing: 2026 Q1 · updated quarterly

📈

Buying streak — 3 quarters in a row

last 6Q
For 3 consecutive quarters, more hedge funds added NERV than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.
🏔️

At the ownership peak (100% of max)

100% of all-time peak
46 hedge funds hold NERV right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.
🚀

Fast accumulation — +119% more funds vs a year ago

fund count last 6Q
+25 new funds entered over the past year (+119% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.
🟢

More buyers than sellers — 68% buying

26 buying12 selling
Last quarter: 26 funds were net buyers (17 opened a brand new position + 9 added to an existing one). Only 12 were sellers (8 trimmed + 4 sold completely). A clear majority buying is a strong confirmation signal.
➡️

Steady new buyers — ~17 new funds per quarter

new funds entering per quarter
Funds opening this position for the first time: 3 → 6 → 14 → 17. A stable flow of new institutional buyers suggests ongoing interest without signs of either acceleration or slowdown.
🔒

41% of holders stayed for 2+ years

■ 41% conviction (2yr+) ■ 13% medium ■ 46% new
19 out of 46 hedge funds have held NERV for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.
💰

Value +119% but shares only +70% — price-driven

Value
+119%
Shares
+69%
Last quarter: the total dollar value of institutional holdings rose +119%, but actual share count only changed +70%. The gap is explained by the stock's price rising — not new buying. Strong value growth with weak share growth means the rally is price momentum, not fresh institutional demand.
🚀

Acceleration phase — new buyers rushing in

3 → 3 → 6 → 14 → 17 new funds/Q
New funds entering each quarter: 3 → 6 → 14 → 17. The pace of institutional discovery is accelerating sharply. This is the 'hot idea' phase — the thesis is being passed from fund to fund. You are not late — the accumulation wave is still building.
🏛️

Veteran-anchored — 47% veterans vs 49% newcomers

■ 47% veterans ■ 4% 1-2yr ■ 49% new
Entry-cohort mix of 47 holders: 22 (47%) are 2+ year veterans, 2 entered 1–2 years ago, and 23 (49%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.
📋

Smaller funds dominant — 15% AUM from top-100

15% from top-100 AUM funds
15 of 46 holders rank in the top 100 by AUM, but together hold only 15% of total institutional value. The stock is held primarily by smaller and mid-sized funds.
5.8
out of 10
Moderate Exit Risk
Exit risk score 5.8/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — NERV

In 2026 Q1, 26 hedge funds were net buyers of NERV (17 opened a new position, 9 added to an existing one), while 12 reduced or exited (8 trimmed, 4 sold completely) — a 68% buyer ratio, indicating clear institutional accumulation. This marks 3 consecutive quarters of net institutional buying — a persistent conviction signal. Net fund flow last quarter: +13 funds (more new holders than closures). Total institutional holders: 46.

Hedge Fund Ownership: NERV

How many hedge funds hold NERV — quarterly history vs. share price
Quarterly hedge fund ownership of NERV vs. share price

Market Analysis: NERV

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: NERV

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Minerva Neurosciences Inc (NERV) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much NERV has moved relative to its sector benchmark (XLV) since the 2026 Q1 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End March 31, 2026 · 78d ago
NERV
-27.5%
XLV
+4.3%

NERV outperformed XLV by -31.8% since March 31, 2026.

Since 13F Filing Date May 15, 2026 · 33d ago
NERV
-16.1%
XLV
+5.4%

Since the filing became public, NERV outperformed XLV by -21.5% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

3 top-rated funds 4 high-conviction
Consensus
2.6
/ 10
breadth
×
Elite
2.8
/ 10
conviction
Hedge Fund Positioning: NERV
46 + Investors

Track Smart Money conviction in NERV. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 46 33 39.39%
13F Shares 39M 23M 69.74%
Total Value $236M $108M 119.04%
New Positions 17 14 +3
Increased Positions 9 8 +1
Closed Positions 4 5 -1
Reduced Positions 8 5 +3
Total Calls 0 0 -
Total Puts 0 0 -
PUT/CALL Ratio 0.0 0.0 Bullish

Statistics: NERV

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q1)

46 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in NERV. Verified SEC 13F-HR filings.

QUARTER:
Top 25 NERV holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Ally Bridge Group (NY) LLC 8.06% 1,655,500 $10.0M
2 Acuta Capital Partners, LLC 3.02% 709,500 $4.3M
3 Foresite Capital Management VI LLC 2.60% 1,986,600 $12.0M
4 Spruce Street Capital LP 2.40% 1,655,500 $10.0M
5 Vivo Capital, LLC 2.17% 4,322,747 $26.0M
6 Trails Edge Capital Partners, LP 1.96% 1,419,000 $8.5M
7 Seven Fleet Capital Management LP 1.70% 889,254 $5.4M
8 Logos Global Management LP 0.97% 3,215,000 $19.4M
9 Seven Fleet Capital Management LP 0.48% 248,476 $1.5M
10 Cannon Global Investment Management, LLC 0.21% 17,758 $107K
11 DV Trading LLC 0.13% 889,254 $5.4M
12 Brendel Financial Advisors LLC 0.12% 41,799 $252K
13 Farallon Capital Management LLC 0.08% 2,365,000 $14.2M
14 Federated Hermes, INC. 0.05% 5,113,224 $30.8M
15 Balyasny Asset Management L.P. 0.03% 4,258,600 $25.7M
16 Adage Capital Partners GP, L.L.C. 0.01% 1,419,000 $8.5M
17 Janus Henderson Group plc 0.01% 4,294,259 $25.9M
18 Apella Capital, LLC 0.00% 42,250 $284K
19 Millennium Management LLC 0.00% 708,291 $4.3M
20 Brevan Howard Capital Management LP 0.00% 28,629 $172K
21 Marshall Wace, LLP 0.00% 218,759 $1.3M
22 Renaissance Technologies LLC 0.00% 89,700 $540K
23 Fortitude Family Office, LLC 0.00% 303 $2K
24 Vanguard Fiduciary Trust Co 0.00% 264,047 $1.6M
25 OMERS ADMINISTRATION Corp 0.00% 10,300 $62K
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Minerva Neurosciences Inc (NERV)

What does the Smart Money Trend signal show for NERV?

Buying streak — 3 quarters in a row: For 3 consecutive quarters, more hedge funds added NERV than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for NERV?

More buyers than sellers — 68% buying: Last quarter: 26 funds were net buyers (17 opened a brand new position + 9 added to an existing one). Only 12 were sellers (8 trimmed + 4 sold completely). A clear majority buying is a strong confirmation signal.

What is the fund quality score for NERV holders?

Smaller funds dominant — 15% AUM from top-100: 15 of 46 holders rank in the top 100 by AUM, but together hold only 15% of total institutional value. The stock is held primarily by smaller and mid-sized funds.

How long have hedge funds held NERV?

41% of holders stayed for 2+ years: 19 out of 46 hedge funds have held NERV for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy Minerva Neurosciences Inc (NERV) following the 2026 Q1 hedge fund 13F filings?

As of today, NERV has moved -16.1% since the 2026 Q1 13F filing date (May 15, 2026), compared to +5.4% for the XLV sector ETF — an outperformance of -21.5%. Since the quarter end (March 31, 2026), NERV has gained -27.5% vs +4.3% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →